|
Market Closed -
NSE India S.E.
12:05:07 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 4,947.00 INR | -1.33% |
|
-2.04% | -10.16% |
| 10-12 | Alkem Laboratories Limited Announces Management Appointments, Effective October 12, 2026 | CI |
| 09-24 | Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Chief Financial Officer | CI |
Company Valuation: Alkem Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 432,909 | 406,055 | 590,890 | 583,680 | 633,575 | 591,488 | - | - |
| Change | - | -6.2% | 45.52% | -1.22% | 8.55% | -6.64% | - | - |
| Enterprise Value (EV) 1 | 433,805 | 393,853 | 587,236 | 578,678 | 632,481 | 578,363 | 563,303 | 554,107 |
| Change | - | -9.21% | 49.1% | -1.46% | 9.3% | -8.56% | -2.6% | -1.63% |
| P/E | 26.3x | 41.3x | 32.9x | 27x | 27.5x | 25.8x | 22.4x | 19.3x |
| PBR | 5.01x | 4.49x | 5.73x | 4.87x | 4.58x | 3.85x | 3.38x | 2.98x |
| PEG | - | -1x | 0.4x | 1.3x | 4.37x | -92.03x | 1.5x | 1.2x |
| Capitalization / Revenue | 4.07x | 3.5x | 4.66x | 4.5x | 4.31x | 3.54x | 3.18x | 2.89x |
| EV / Revenue | 4.08x | 3.4x | 4.64x | 4.46x | 4.3x | 3.46x | 3.03x | 2.71x |
| EV / EBITDA | 21.1x | 24.5x | 26.2x | 23x | 21x | 16.9x | 14.3x | 12.5x |
| EV / EBIT | 24.8x | 30.3x | 30.2x | 26.9x | 24.1x | 19.5x | 16.5x | 14.1x |
| EV / FCF | 55.4x | 27.1x | 33.3x | 45.3x | 42.8x | 56.1x | 27.6x | 21.7x |
| FCF Yield | 1.81% | 3.69% | 3% | 2.21% | 2.33% | 1.78% | 3.63% | 4.61% |
| Dividend per Share 2 | 34 | 25 | 40 | 45 | 53 | 50.29 | 55.4 | 63.85 |
| Rate of return | 0.94% | 0.74% | 0.81% | 0.92% | 1% | 1.02% | 1.12% | 1.29% |
| EPS 2 | 137.6 | 82.31 | 150.2 | 181.1 | 192.5 | 192 | 221 | 256.1 |
| Distribution rate | 24.7% | 30.4% | 26.6% | 24.8% | 27.5% | 26.2% | 25.1% | 24.9% |
| Net sales 1 | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 | 166,949 | 186,008 | 204,727 |
| EBITDA 1 | 20,529 | 16,094 | 22,455 | 25,122 | 30,052 | 34,204 | 39,337 | 44,427 |
| EBIT 1 | 17,490 | 12,990 | 19,462 | 21,550 | 26,232 | 29,661 | 34,151 | 39,180 |
| Net income 1 | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 | 23,147 | 27,276 | 31,030 |
| Net Debt 1 | 896.1 | -12,202 | -3,654 | -5,003 | -1,094 | -13,125 | -28,185 | -37,381 |
| Reference price 2 | 3,620.70 | 3,396.10 | 4,942.00 | 4,881.70 | 5,299.00 | 4,947.00 | 4,947.00 | 4,947.00 |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Announcement Date | 13/05/22 | 19/05/23 | 29/05/24 | 29/05/25 | 28/05/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 25.77x | 3.46x | 16.91x | 1.02% | 6.23B | |
| 36.74x | 13.1x | 27.8x | 0.54% | 1,135B | |
| 38.61x | 6.5x | 18.29x | 2.02% | 636B | |
| 36.46x | 8.38x | 17.29x | 2.41% | 505B | |
| 20.87x | 5.11x | 12.73x | 2.56% | 378B | |
| 105.89x | 5.92x | 25.41x | 2.34% | 358B | |
| 21.76x | 5.67x | 13.94x | 2.81% | 295B | |
| 22.42x | 4.53x | 12.96x | 1.95% | 266B | |
| 27.87x | 7.16x | 12.81x | 2.3% | 237B | |
| -45.48x | 6.98x | 27.06x | 2.11% | 193B | |
| Average | 29.09x | 6.68x | 18.52x | 2.01% | 401.06B | |
| Weighted average by Cap. | 35.12x | 8.29x | 20.39x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALKEM Stock
- Valuation Alkem Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
